What is PT-141?
PT-141 is a melanocortin agonist used to treat sexual dysfunction in both men and women. It acts on the central nervous system to increase libido and arousal.
Research classification: Research summary · not a validated human regimen. The PT-141 10 mg vial label reports nominal content; it does not state a suitable amount for human use.
Mechanism and research questions
In test subjects, bremelanotide acts as a non-selective melanocortin receptor agonist (MC3R/MC4R). Central MC4R activation enhances dopamine release in reward and arousal regions; it does not directly act on the nitric oxide pathway.
Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.
How to read a reported schedule
The earlier catalogue entry described research examples, not a clinically validated schedule for people. The dose, route, frequency or escalation used in one experiment cannot be generalised to a different formulation or to an individual. When primary evidence is not available, do not treat a catalogue number as a recommendation.
For the existing schedule, its evidence caveats and the concentration calculator, see the PT-141 protocol and vial reference. Figures displayed there are research context, not a personalised prescription.
Vial identity and preparation
An exact-matching Peak Peptides Australia 10 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.
Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.
View Peak Peptides Australia's research-only listing and confirm its current labelled strength.
Sources, limits and next steps
For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.